O
Orchestra BioMed Holdings, Inc.
OBIOCIK 0001814114NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31
Period
FY 2025
Revenue
$33.48M
Net Income
$-52.70M
Total Assets
$114.86M
Equity
$53.57M
Shares Out
59.88M
Op. Cash Flow
$-48.96M
Business
Orchestra BioMed Holdings, Inc. is a biomedical innovation company developing late-stage medical device product candidates through partnership-enabled collaborations with major device manufacturers. Its flagship products are AVIM Therapy, a bioelectronic treatment for uncontrolled hypertension delivered via cardiac pacemakers under an exclusive agreement with Medtronic, and Virtue SAB, a drug-device combination balloon for treating arterial restenosis. The company pursues a risk-reward-sharing model, focusing on clinical development while partners handle commercialization, with operations spanning bioelectronic therapies and interventional cardiovascular devices.
Summary from 10-K filed 2026-03-12
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 33 | 3 | 3 | 4 | — | |
| Cost of product revenues | 190,000 | 204,000 | 186,000 | 211,000 | — | |
| Research and development | 58 | 43 | 34 | 22 | — | |
| Selling, general and administrative | 27 | 24 | 20 | 14 | — | |
| Total expenses | 85 | 67 | 54 | 36 | — | |
| Loss from operations | −52 | −64 | −52 | −33 | −394,756 | |
| Interest (expense) income, net | −1 | 3 | 4 | — | — | |
| Change in the fair value of derivative liability | 254,000 | — | — | — | — | |
| Loss on fair value of strategic investments | — | −68,000 | −18,000 | 1 | — | |
| Other expense | — | −11,000 | — | — | — | |
| Total other (expense) income | −894,000 | 3 | 2 | −951,000 | — | |
| Net loss | −53 | −61 | −49 | −34 | −378,753 | |
| Adjustment to carrying value of Series A Preferred Stock | −254,000 | — | — | — | — | |
| Net loss attributable to common stockholders | −53 | −61 | — | — | — | |
| Basic (in dollars per share) | −1.11 | −1.66 | −1.48 | −2.24 | −0.02 | |
| Diluted (in dollars per share) | −1.11 | −1.66 | −1.48 | −2.24 | −0.02 | |
| Weighted-average shares used in computing net loss attributable to common stockholders per share, basic (in shares) | 48 | 37 | 33 | 15 | 20 | |
| Weighted-average shares used in computing net loss attributable to common stockholders per share, diluted (in shares) | 48 | 37 | 33 | 15 | 20 | |
| Unrealized gain on marketable securities | 8,000 | 62,000 | −2,000 | −8,000 | — | |
| Comprehensive loss | −53 | −61 | −49 | −34 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 35 | 22 | 31 | 20 | 2 | |
| Marketable securities | 72 | 45 | 57 | 64 | — | |
| Accounts receivable, net | 95,000 | 92,000 | 99,000 | 96,000 | — | |
| Inventory | 310,000 | 173,000 | 146,000 | 276,000 | — | |
| Prepaid expenses and other current assets | 994,000 | 2 | 1 | 533,000 | — | |
| Total current assets | 108 | 69 | 89 | 85 | 2 | |
| Property and equipment, net | 2 | 1 | 1 | 1 | — | |
| Right-of-use assets | 1 | 2 | 2 | 2 | — | |
| Strategic investments | 2 | 2 | — | — | — | |
| Deposits and other assets | 1 | 1 | 769,000 | 5 | — | |
| TOTAL ASSETS | 115 | 76 | 95 | 96 | 162 | |
| Accounts payable | 6 | 5 | 3 | 4 | 1,388 | |
| Accrued expenses and other liabilities | 10 | 6 | 5 | 5 | 14,151 | |
| Operating lease liability, current portion | 751,000 | 550,000 | 649,000 | 697,000 | — | |
| Deferred revenue, current portion | — | 4 | 3 | 6 | — | |
| Total current liabilities | 17 | 16 | 11 | 19 | 165,539 | |
| Deferred revenue, less current portion | — | 11 | 15 | 13 | — | |
| Royalty purchase agreement | 16 | — | — | — | — | |
| Loan payable | 14 | 14 | — | 9 | — | |
| Derivative liability | 3 | — | — | — | — | |
| Operating lease liability, less current portion | 936,000 | 2 | 1 | 2 | — | |
| Other long-term liabilities | 308,000 | 40,000 | — | 196,000 | — | |
| TOTAL LIABILITIES | 51 | 43 | 27 | 43 | 6 | |
| Series A Preferred Stock, $0.0001 par value per share; 200,000 issued and outstanding at December 31, 2025 and 0 issued and outstanding at December 31, 2024; aggregate liquidation preference of $20,000 at December 31, 2025 | 10 | — | — | — | — | |
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; | — | — | — | — | — | |
| Common stock, $0.0001 par value per share; 340,000,000 shares authorized; 57,032,963 and 38,194,442 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively. | 6,000 | 4,000 | 4,000 | 2,000 | 445 | |
| Additional paid-in capital | 416 | 343 | 317 | 252 | — | |
| Accumulated other comprehensive income | 60,000 | 52,000 | −10,000 | −8,000 | — | |
| Accumulated deficit | −363 | −310 | −249 | −200 | −4 | |
| TOTAL STOCKHOLDERS' EQUITY | 54 | 33 | 68 | 53 | −20 | |
| TOTAL LIABILITIES, SERIES A PREFERRED STOCK AND STOCKHOLDERS' EQUITY | 115 | 76 | 95 | 96 | 162 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −53 | −61 | −49 | −34 | — | |
| Depreciation and amortization | 327,000 | 308,000 | 287,000 | 222,000 | — | |
| Stock-based compensation | 12 | 11 | 8 | 3 | — | |
| Acquired in-process research and development | 0 | 1 | 0 | — | — | |
| Non-cash interest expense on liability related to the royalty purchase agreement | 2 | — | — | — | — | |
| Accretion and interest related to marketable securities | −811,000 | −2 | −4 | −600,000 | — | |
| Non-cash lease expense | 607,000 | 654,000 | 632,000 | 571,000 | — | |
| Amortization of deferred financing fees | 215,000 | 31,000 | 112,000 | 163,000 | — | |
| Other | — | 11,000 | — | — | — | |
| Accounts receivable | −3,000 | 22,000 | −3,000 | 25,000 | — | |
| Inventory | −137,000 | −28,000 | 131,000 | −208,000 | — | |
| Prepaid expenses and other assets | 880,000 | −1 | −781,000 | −439,000 | — | |
| Accounts payable, accrued expenses and other liabilities | 5 | 3 | 145,000 | 3 | — | |
| Operating lease liabilities - current and non-current | −550,000 | −652,000 | −693,000 | −319,000 | — | |
| Deferred revenue | −15 | −2 | −2 | −3 | — | |
| Net cash used in operating activities | −49 | −51 | −46 | −29 | −272,362 | |
| Purchases of property and equipment | −489,000 | −289,000 | −78,000 | −591,000 | — | |
| Sales of marketable securities | 50 | 87 | 153 | — | — | |
| Purchases of marketable securities | −76 | −73 | −142 | −63 | — | |
| Asset acquisition, net of cash acquired | — | −602,000 | — | — | — | |
| Net cash (used in) provided by investing activities | −27 | 13 | 11 | −64 | — | |
| Proceeds from sale of common stock and pre-funded warrants, net of issuance costs | 58 | — | — | — | — | |
| Proceeds from the royalty purchase agreement | 20 | — | — | — | — | |
| Proceeds from issuance of Series A preferred stock | 13 | — | — | — | — | |
| Repayment of royalty liability | −972,000 | — | — | — | — | |
| Proceeds from Hercules term loan | — | 15 | — | 10 | — | |
| Proceeds from At-The-Market offering, net of issuance costs | 2 | 15 | — | — | — | |
| Proceeds from exercise of stock options | 91,000 | 240,000 | 231,000 | 121,000 | — | |
| Restricted stock units withheld for tax | −2 | −550,000 | — | — | — | |
| Deferred financing costs | −1 | −554,000 | — | — | — | |
| Net cash provided by financing activities | 88 | 29 | 46 | 103 | — | |
| Net increase (decrease) in cash and cash equivalents | 12 | −8 | 11 | 10 | −272,362 | |
| Interest | 1 | 102,000 | 1 | 1 | — | |
| Operating lease right-of-use asset obtained in exchange for new operating lease liabilities | — | 1 | — | — | — | |
| Increase in accounts payable, accrued expenses and other liabilities related to fixed assets | 169,000 | — | — | — | — | |
| Common stock issued pursuant to asset acquisition | — | 352,000 | — | — | — | |
| Warrants issued pursuant to debt financing | 239,000 | 185,000 | 66,000 | — | — | |
| Warrants issued pursuant to the royalty purchase agreement | 3 | — | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Orchestra BioMed Holdings, Inc.'s CIK number?
Orchestra BioMed Holdings, Inc.'s SEC CIK number is 0001814114 (1814114). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Orchestra BioMed Holdings, Inc.'s SEC filings?
All of Orchestra BioMed Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.